It was found that women with LKB1-deficient EC had elevated levels of the pro-TAMs recruitment chemokine CCL-2 in peripheral blood serum, suggesting that CCL-2 produced by the tumor-bearing uterus can enter the circulation and that serum CCL-2 may be used as a potential circulating biomarker to monitor tumor progression or predict progression risk, but this is still at an early stage and not supported by relevant data (23). Here, CCL2 is linked to neoplasm.